- Home
- MARPS vs SLXN Comparison
MARPS vs SLXN Comparison
Compare MARPS & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- SLXN
- Stock Information
- Founded
- MARPS 1956
- SLXN 2008
- Country
- MARPS United States
- SLXN Israel
- Employees
- MARPS N/A
- SLXN N/A
- Industry
- MARPS Oil & Gas Production
- SLXN
- Sector
- MARPS Energy
- SLXN
- Exchange
- MARPS Nasdaq
- SLXN NYSE
- Market Cap
- MARPS 7.8M
- SLXN 6.9M
- IPO Year
- MARPS N/A
- SLXN N/A
- Fundamental
- Price
- MARPS $3.75
- SLXN $0.95
- Analyst Decision
- MARPS
- SLXN Strong Buy
- Analyst Count
- MARPS 0
- SLXN 1
- Target Price
- MARPS N/A
- SLXN $5.00
- AVG Volume (30 Days)
- MARPS 12.2K
- SLXN 1.2M
- Earning Date
- MARPS 01-01-0001
- SLXN 05-13-2025
- Dividend Yield
- MARPS 10.21%
- SLXN N/A
- EPS Growth
- MARPS N/A
- SLXN N/A
- EPS
- MARPS 0.36
- SLXN N/A
- Revenue
- MARPS $1,036,019.00
- SLXN N/A
- Revenue This Year
- MARPS N/A
- SLXN N/A
- Revenue Next Year
- MARPS N/A
- SLXN N/A
- P/E Ratio
- MARPS $10.31
- SLXN N/A
- Revenue Growth
- MARPS N/A
- SLXN N/A
- 52 Week Low
- MARPS $3.34
- SLXN $0.58
- 52 Week High
- MARPS $5.20
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- MARPS 39.77
- SLXN N/A
- Support Level
- MARPS $3.70
- SLXN N/A
- Resistance Level
- MARPS $3.97
- SLXN N/A
- Average True Range (ATR)
- MARPS 0.09
- SLXN 0.00
- MACD
- MARPS -0.01
- SLXN 0.00
- Stochastic Oscillator
- MARPS 18.52
- SLXN 0.00
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.